Howland Capital Management LLC Grows Position in Bristol-Myers Squibb (NYSE:BMY)

Howland Capital Management LLC grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,929 shares of the biopharmaceutical company’s stock after purchasing an additional 364 shares during the period. Howland Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,352,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of BMY. Northwest Financial Advisors purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $27,000. Accordant Advisory Group Inc purchased a new stake in Bristol-Myers Squibb in the 1st quarter worth approximately $31,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $34,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BMO Capital Markets reduced their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Finally, Barclays reduced their target price on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $59.50.

Bristol-Myers Squibb Trading Down 0.9 %

Bristol-Myers Squibb stock traded down $0.38 during midday trading on Thursday, reaching $40.75. 17,883,034 shares of the stock traded hands, compared to its average volume of 15,683,951. The company has a 50-day simple moving average of $42.05 and a two-hundred day simple moving average of $47.52. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $65.38. The firm has a market cap of $82.59 billion, a PE ratio of -13.25, a price-to-earnings-growth ratio of 13.68 and a beta of 0.44. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.05 EPS. Research analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.89%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.